Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

402 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting calcium signaling to cure auto-immune diseases KALSIOM is a biotech company founded in April 2020 and based in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes. Immunology and Therapeutic antibodies

53 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

World leaders in neutrophil immunotherapies to rejuvenate immune competence in solid tumours and beyond! LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

131 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering immune interventions to treat chronic disease AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineered Immunity Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unravelling immune system function, one cell at a time Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

The Immune system under control Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating a future where inflammatory disorders are curable Bastion Therapeutics is a preclinical stage biotech with a mission to develop novel Treg cell therapies to address the unmet clinical need for inflammatory disorders. We leverage our proprietary GRITTM platform technology to engineer Tregs to modulate the immune system and overcome challenges associated with previous generations of Treg cell therapies. Our vision is to provide life-changing therapies that are efficacious, durable and safe to patients suffering from inflammatory disorders.

56 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

214 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing therapies to patients with cancer and autoimmune diseases.

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New solutions for autoimmune, inflammatory and bone diseases. BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of immunity, auto-immune diseases and organ repair. Cell therapy, Bone and joint tissue regeneration, Osteo-Articular Diseases, autoimmunity, immunity, autoimmune disease, and arsenic

85 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

150 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy. The company builds on ground-breaking and proprietary reprogramming technologies to develop gene therapy products designed to set in motion efficient and personalized immune responses. Backed by top investors, Asgard Therapeutics aims to establish a pipeline of off-the shelf cancer immunotherapies that trigger personalized anti-cancer immune responses for the benefit of cancer patients in need. Cell Reprogramming, Cancer Immunotherapy, and Dendritic cells

144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering thymus-empowered T-cell platform to fight cancer and infection Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T …

51 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Designing functional antibodies for the most challenging targets. Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. Machine Learning, Antibodies, and Drug discovery

103 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Generative A.I. Synthetic Biology

Exploiting a new class of tumour specific antigens for cancer therapy A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen. TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Amplifying nature’s innate intelligence to fight cancer ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with …

14 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making tissue therapeutics possible to defeat serious disease Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell’s first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable …

33 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Genewity is a pioneering biotech start-up focused on advanced thymus-driven therapies for immune reconstitution. Supported by the extensive business expertise of our management and advisors, we are at the forefront of developing and commercialising breakthrough therapies. With over 150 years of combined experience in immunology and gene therapy, our team is uniquely positioned to drive advancements in the field.

273 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Maximizing Immunoassays Performances InfYnity Biomarkers was founded in 2009 in Lyon (France). We are an R&D In-Vitro Diagnostics Company fully dedicated to infectious diseases and immunity. Company Mission: Maximizing Immunoassay Performance i.e. we have the ambition to set new criteria for immunoassays: study the diversity of immune response to provide high-value information instead of the binary response. Our Offer: - High quality, custom-made biomaterial (antigens and antibodies) - RUO Multiplex Immunoassays - Tailored immunobiology services ranging from biomaterial design to biomarker discovery and immunoassay development. Our originality and strength relies on a unique combination of proven skills: Multiplex technology AND …

90 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

184 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building the future of AI drug development with the data that matters. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning

115 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology SaaS A.I. Generative A.I.

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing

71 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Versatile immunotherapy for personalized cancer medicine Inovactis develops an innovative treatment against cancer at the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. personalized immunotherapy and medicine

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK

118 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Immunotherapy against senescence StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.

70 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

157 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Crossing the next frontier, to give you a fair chance to fight Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms. Inflammatory Bowel Diseases, Live Biotherapeutics, Microbiome, Immunotherapies, Immuno-oncology, and Immuno-inflammation

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Modulating innate immunity to improve cancer therapy outcomes. . Akthelia Pharma is a late preclinical-stage immunotherapy company, with its HQ in Iceland, targeting a huge unmet opportunity to improve cancer and cell/organ transplant outcomes through reducing the risk of neutropenic sepsis. This potentially fatal complication of systemic anticancer treatment, where a combination of reduced neutrophil count and loss of GI integrity results in bacteremia from the patient's own microbiome, is the leading cause of death associated with chemotherapy (up to 20% mortality) -- other than disease progression. Our breakthrough patented strategy, which is supported by world-leading KOLs, is to specifically …

22 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and …

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the full potential of cell therapies for patients around the world SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics. Our goal is to create well-tolerated cell therapies that can provide therapeutic benefit for patients and improve the patient experience over existing cell therapy approaches. With accelerated production timelines under …

83 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers. Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs …

42 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Living Immunotherapies Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Immunotherapies and T Cell receptors TCR

56 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

162 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

265 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

LIVING CURES Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Biotechnology, Vaccines, Oral delivery, Immunology, Synthetic Biology, Oncology, Microbial Immunotherapy, and Immunotherapy

123 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class ADCs tailor designed to attack advanced cancer Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

410 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Rewriting immunotherapy. Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

9 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Restoring immune surveillance through natural immunity - a revolution in dendritic cell therapy. Transimmune AG is leading a revolution in dendritic cell therapy having uncovered how dendritic cells are made physiologically in vivo.

12 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Actor of change Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development. Anticorps, Custom antibody development, Antibody, Développement sur mesure de génération d'anticorps, IgY, Chicken, Poulet, ELISA, Therapeutic Antibodies, Recombinant Antibodies, Humanized Antibodies, GPCRs, and Oncology

91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers. oncology, immune-evasive, and AXL

154 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Kuur is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of T cells, called natural killer T cells (NKT cells) and innovative chimeric antigen receptor (CAR) construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors. Immunotherapy, Cancer, Oncology, T cells, TCR, CAR, CAR-NKT, clinical trial, NKT Cells, celltherapy, and lifesciences

75 similar entities Type: SMB Activities: biotech deeptech transporttech Technologies: Synthetic Biology

Precision Cancer Immunotherapy At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immune oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction through activation of tumor-residing macrophages. By leveraging insights from natural metabolic processes, we develop small molecule therapies that enhance the body’s native immune response against cancer. Biotech, Therapeutics, and Immuno-oncology

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology